Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600062's EV-to-EBITDA is ranked better than 67.57% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs SHSE:600062: 8.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Resources Double-Crane Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
China Resources Double-Crane Pharmaceutical Co's share price for today is ¥16.09.
China Resources Double-Crane Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.558.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co EV-to-EBITDA Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
China Resources Double-Crane Pharmaceutical Co's current Enterprise Value is ¥16,091 Mil.
China Resources Double-Crane Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,836 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a EV-to-EBITDA of 8.77 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Resources Double-Crane Pharmaceutical Co. This is 10% below median its historical median of 9.78. Over the past decade, China Resources Double-Crane Pharmaceutical Co's EV-to-EBITDA has ranged from 6.77 to 27.25. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #238 out of 734 companies in the Drug Manufacturers industry, placing it in the top 32.4%.
Is China Resources Double-Crane Pharmaceutical Co's EV-to-EBITDA too high?
China Resources Double-Crane Pharmaceutical Co's current EV-to-EBITDA of 8.77 is 10% below median its 10-year median of 9.78. Over the past 10 years, this metric has ranged from a low of 6.77 to a high of 27.25. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. China Resources Double-Crane Pharmaceutical Co's value of 8.77 is 32.7% below this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #238 out of 734 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #238 out of 734 companies for EV-to-EBITDA. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.03. China Resources Double-Crane Pharmaceutical Co's value of 8.77 is 32.7% below this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own EV-to-EBITDA has ranged from 6.77 to 27.25 over the past decade. While the company's 10-year median is 9.78 vs. the industry median of 13.03, China Resources Double-Crane Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current EV-to-EBITDA of 8.77 is 32.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Resources Double-Crane Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current EV-to-EBITDA is 8.77, which is 10% below median its own 10-year median of 9.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.72, compared to a current price of ¥16.09 — trading 14% below its estimated fair value. The current EV-to-EBITDA is 8.77, which is 10% below median its 10-year median of 9.78 and 32.7% below the Drug Manufacturers industry median of 13.03. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current EV-to-EBITDA is 8.77 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.09 is trading 14% below its estimated GF Value™ of ¥18.72.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
EV-to-EBITDA: 8.77 (10% below median its 10-year median of 9.78)
GF Value™: ¥18.72 vs. price of ¥16.09 (14% below fair value)
Industry Position: 32.7% below the Drug Manufacturers median (#238 of 734)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
92GF Score
Get the complete analysis for SHSE:600062
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
